Choi, Byung Hyun,Lee, Jun Kyung,Kim, Jong Gyun,Nam, Su Youn,Lee, June Hyung,Park, Ju Young,Lee, Na Rae,Kim, Ki Hong,Kim, Seul Gi,Oh, Se Woong,Shin, Seung Yub,Kang, Ho Woong,Ahn, Su Jin,Chung, Soo Yong
申请号：
NZ74861417
公开号：
NZ748614A
申请日:
2017.04.19
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
Provided is a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof. More particularly, a fusion protein comprising a wild-type human CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection. In a particular embodiment, the CCL3 variant comprises SEQ ID NO: 3 and comprises the following mutations: 1) deletion of N-terminal amino acid(s) alanine, or alanine and proline, and 2) substitution of aspartic acid to alanine at position 27. The CCL3 variant is linked to the Fc fragment with a linker having the following formula: (RNT)nGRGG(EEKKK)m wherein n and m are respectively 1 to 5.
